Guselkumab Q4W and Q8W showed comparable safety and efficacy for treating active PsA among patients with an inadequate response to 1 TNF inhibitor.

Starting a TNF inhibitor within 1 year of the onset of back pain may not improve clinical outcomes or drug retention compared with starting therapy after axial spondyloarthritis is established.

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...

Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc.

The updated indications state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy. The Food ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for cases where a patient may not be appropriate for a TNF blocker, drugmaker ...

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is ...